Chemcon Speciality Chemicals Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/pl6dtvuerhvenjhrizuek4nx.pdf

Key Takeaways


HMDS: The Margin Reset

Kamal Aggarwal: "HMDS, cannot comment that the margins will remain consistent, because we have been enjoying this margin since more than five years. I feel now it should start reducing to some extent from maybe marginally."

Bromides & Bromobenzene: The Offset


New Product Pipeline: Guanine & P10


CMIC: Modest Improvement, Modest Outlook


Strategy: Diluting Concentration, Adding Locations

Kamal Aggarwal: "We want to dilute our concentrations on these two products in particular... We don't want to concentrate on particular products."

Margin Trajectory & The Information Gap

Kamal Aggarwal: "This period, in the present one or two quarters, if you see the margins, there have been a pressure that should not be considered as a base for the business deviation. We need to wait for a couple of quarters more to understand the line or the direction for the margins."

Guidance & Commitments

CommitmentSpecificsTimeline
Guanine commissioningAwaiting final local authority approvals; figures to start reflecting in P&LQ4 FY23 (no further delay expected)
Guanine ramp-upRun at full capacity; 85%–90% utilization expected in FY24Maximum one quarter from commissioning
P10 plant commissioningCommercial production start; no regulatory approval needed beyond PCB clearance already obtainedQ1 FY24
P10 plant full capacityFull ramp-upFY25
Bromobenzene utilization~75% utilization expectedFY24
Bromide business momentumSustained oil field chemicals sales, backed by raw material import contractsCurrent year and next year
HMDS Q4 volumesBetter than Q3 volumeQ4 FY23
HMDS marginsExpected to remain lowerCurrent quarter and maybe one more quarter
Raw material contract coverageOne-year contract signed covering 35%–40% of total requirement; working on contracting the remaining domestic portionCalendar year 2023
New land developmentPlanning starts after non-agriculture conversion permissionsMay take a couple of years

Key Metrics

MetricQ3 FY23
Revenue₹77 cr, +54% YoY
Domestic revenue share~40%, international ~60%
EBITDA₹14 cr, margin 17.6%
Net profit₹11 cr, margin 14.9%
Total production volume2,323 metric tons, vs 1,333 metric tons in Q3 FY22
HMDS revenue₹27 cr, ~36% of total revenue
CMIC revenue₹11 cr, ~15% of total revenue
Bromide revenue₹28 cr, ~38% of total revenue
Bromobenzene revenue₹7 cr, ~9% of total revenue
Bromobenzene volume sold252 metric tons
HMDS current price~₹650, nearly stable QoQ
CMIC current price~₹400, nearly stable QoQ
Guanine capacity50 tons per month, 600 tons per year
Guanine expected margin~25%
P10 plant capex₹22 cr, commissioning expected Q1 FY24